1Patrono C,Coller B,FitzGerald GA,et al.Platelet-active drugs:the relationships among dose,effectiveness,and side effects:the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.Chest,2004,126(3 Suppl):234S-264S.
2Pearson TA,Blair SN,Daniels SR,et al.AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke:2002 Update:Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases.American Heart Association Science Advisory and Coordinating Committee.Circulation,2002,106:388-391.
3Ridker PM,Cook NR,Lee IM,et al.A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.N Engl J Med,2005,352:1293-1304.
4Antithrombotic Trialists' Collaboration.Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death,myocardial infarction,and stroke in high risk patients.BMJ,2002,324:71-86.
5Yusuf S,Zhao F,Mehta SR,et al.Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.N Engl J Med,2001,345:494-502.
6Juul-Moller S,Edvardsson N,Jahnmatz B,et al.Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris.Lancet,1992,340:1421-1425.
7Mehta SR,Yusuf S,Peters RJ,et al.Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention:the PCI-CURE study.Lancet,2001,358:527-533.
8Aspirin effects on mortality and morbidity in patients with diabetes mellitus.Early Treatment Diabetic Retinopathy Study report 14.ETDRS Investigators.JAMA,1992,268:1292-1300.
9Eikelboom JW,Hirsh J,Weitz JI,et al.Aspirin resistant thromboxane biosynthesis and the risk of myocardial infarction,stroke,or cardiovascular death in patients at high risk for cardiovascular events.Circulation,2002,105:1650-1655.
10Alexander JH,Harrington RA,Tuttle RH,et al.Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes.PURSUIT Investigators.Platelet Ⅱb/Ⅲa in Unstable angina:Receptor Suppression Using Integrilin Therapy.Am J Cardiol,1999,83:1147-1151.
